company background image
HRGN logo

Harvard Apparatus Regenerative Technology OTCPK:HRGN Stock Report

Last Price

US$3.00

Market Cap

US$40.9m

7D

-4.8%

1Y

-49.5%

Updated

26 Mar, 2024

Data

Company Financials

Harvard Apparatus Regenerative Technology Inc.

OTCPK:HRGN Stock Report

Market Cap: US$40.9m

HRGN Stock Overview

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, engages in developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway resulting from cancer, trauma, or birth defects.

HRGN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Harvard Apparatus Regenerative Technology Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Harvard Apparatus Regenerative Technology
Historical stock prices
Current Share PriceUS$3.00
52 Week HighUS$6.48
52 Week LowUS$2.13
Beta-1.48
1 Month Change-21.05%
3 Month Change-39.64%
1 Year Change-49.49%
3 Year Change118.18%
5 Year Change37.61%
Change since IPO-97.50%

Recent News & Updates

Recent updates

Shareholder Returns

HRGNUS BiotechsUS Market
7D-4.8%-0.5%0.6%
1Y-49.5%9.6%29.5%

Return vs Industry: HRGN underperformed the US Biotechs industry which returned 10.2% over the past year.

Return vs Market: HRGN underperformed the US Market which returned 29.8% over the past year.

Price Volatility

Is HRGN's price volatile compared to industry and market?
HRGN volatility
HRGN Average Weekly Movement19.0%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: HRGN's share price has been volatile over the past 3 months.

Volatility Over Time: HRGN's weekly volatility has increased from 14% to 19% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20098Jerry Hehttps://www.hregen.com

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, engages in developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway resulting from cancer, trauma, or birth defects. The company’s pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease.

Harvard Apparatus Regenerative Technology Inc. Fundamentals Summary

How do Harvard Apparatus Regenerative Technology's earnings and revenue compare to its market cap?
HRGN fundamental statistics
Market capUS$40.92m
Earnings (TTM)-US$8.60m
Revenue (TTM)US$40.00k

1,046x

P/S Ratio

-4.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HRGN income statement (TTM)
RevenueUS$40.00k
Cost of RevenueUS$13.00k
Gross ProfitUS$27.00k
Other ExpensesUS$8.62m
Earnings-US$8.60m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.62
Gross Margin67.50%
Net Profit Margin-21,490.45%
Debt/Equity Ratio0%

How did HRGN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.